Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Owning your premises is still a great option

The Scottish Intercollegiate Guidelines Network moved closer to a 4mmol/l total cholesterol target after agreeing it would be clinically effective.

SIGN is to examine the cost-effectiveness of lowering the cholesterol target for secondary prevention of CHD

after a 'positive response' to its draft proposals at a meeting in Edinburgh this week.

NICE said it would consider the SIGN guidance in its own review of statins use, but would not confirm whether it would take the same view.

Dr James Grant, chair of the SIGN CHD prevention guideline group, said: 'This is a target we believe evidence supports for secondary prevention and not for primary prevention. That was in general positively received by the meeting.'

Dr Grant, a GP in Auchterader, Perthshire, added: 'To do this would involve the prescribing of a large amount of statins and other drugs, with obvious cost issues.'

SIGN released draft guidance recommending the 4mmol/l target in August and plans to release final guidance next spring, following findings from a newly commissioned cost-effectiveness analysis.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say